Evidence Explorer · MS-N226 · Nutrition and survivorship · Appraised November 3, 2026
Among participants in an adjuvant chemotherapy trial, higher postdiagnosis dietary glycemic load was associated with worse disease-free, recurrence-free and overall survival. Because diet was not randomized, the result cannot prove that lowering glycemic load prevents recurrence.
Evidence at a glance
Benefit signal: No benefit claim; higher exposure associated with worse outcomes
Certainty: Low for causality
Risk context: Overly restrictive carbohydrate avoidance can worsen weight loss or treatment tolerance
What was studied
The prospective observational companion study included 1,011 people with stage III colon cancer who reported diet during and six months after adjuvant chemotherapy.
Highest versus lowest quintile of glycemic load was associated with adjusted HR 1.79 (95% CI 1.29–2.48) for disease-free survival. The association was stronger among participants with BMI at least 25 kg/m² (HR 2.26, 95% CI 1.53–3.32).
What this evidence cannot establish
This was not a diet trial. Residual confounding, dietary measurement error and changes caused by illness can produce or exaggerate associations.
Glycemic load is not the same as eliminating carbohydrates. The study does not establish a ketogenic diet, supplement or glucose-lowering drug as cancer treatment.
Practical safety context
People losing weight or struggling to eat during treatment may be harmed by restrictive diets. Diabetes medicines may require adjustment when carbohydrate intake changes.
Prioritize adequate calories and protein, whole-food carbohydrate sources and individualized glucose management rather than an unsupported cure diet.
Questions for the care team
- Am I weight-stable enough to change carbohydrate quality or quantity?
- How should diabetes treatment change if my eating pattern changes?
- Can a dietitian help improve food quality without reducing needed calories?
Sources
- CALGB 89803 prospective observational analysis (PMID 23136358)
Sources and publication status checked November 3, 2026. The parent chemotherapy trial does not make this dietary exposure randomized.
For education, not personal medical advice. Nutrition and supplement decisions during cancer care should be individualized with the oncology and dietetics teams.
